Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer

Mizukami,Tatsuzo; Kamachi,Hirofumi; Mitsuhashi,Tomoko; Einama,Takahiro; Hatanaka,Yutaka; Kamiyama,Toshiya; Taketomi,Akinobu

doi:10.3892/ol.2018.9499

Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer

Authors:
- Tatsuzo Mizukami
- Hirofumi Kamachi
- Tomoko Mitsuhashi
- Takahiro Einama
- Yutaka Hatanaka
- Toshiya Kamiyama
- Akinobu Taketomi
View Affiliations

Affiliations: Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060‑8638, Japan, Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido 060‑8648, Japan
Published online on: September 25, 2018 https://doi.org/10.3892/ol.2018.9499
Pages: 6423-6430
Copyright: © Mizukami et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prominin‑1 (CD133) is one of the most important stem cell markers among various malignant tumor types, but the clinicopathological significance of CD133 expression in intrahepatic cholangiocarcinoma remains controversial. To the best of our knowledge, there have been no reports on extrahepatic bile duct cancer (EHBDCA) and gallbladder cancer (GBCA). The present study examined the clinicopathological significance of CD133 expression in EHBDCA and GBCA. Immunohistochemistry was used to evaluate CD133 expression in resected specimens obtained from 82 patients with EHBDCA and GBCA, and this expression was compared with the clinicopathological parameters and survival data of the patients. Cytoplasmic CD133 expression was identified in 20 patients, and its incidence was significantly associated with histopathological grade (P=0.035), pT factor (P=0.020) and recurrence (P=0.046). Survival analysis revealed that cytoplasmic CD133 expression in patients was significantly associated with a poorer overall survival (OS) and relapse‑free survival (RFS) compared with those without cytoplasmic expression (5‑year OS rate, 11.6% vs. 39.1%; 3‑year RFS rate, 12.5% vs. 42.0%, respectively). Multivariate analysis revealed that cytoplasmic CD133 expression was an independent prognostic factor for OS and RFS (P=0.0036 and P<0.0001, respectively). To the best of our knowledge, this is the first report demonstrating that cytoplasmic CD133 expression was associated with histologic differentiation, cancer progression, recurrence and poor prognosis in EHBDCA and GBCA. CD133 expression may be a useful marker for clinical prognosis in patients with EHBDCA and GBCA.

View Figures

View References

1	Ruzzenente A, Iacono C, Conci S, Bertuzzo F, Salvagno G, Ruzzenente O, Campagnaro T, Valdegamberi A, Pachera S, Bagante F and Guglielmi A: A novel serum marker for biliary tract cancer: Diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC). Surgery. 155:633–639. 2014. View Article : Google Scholar : PubMed/NCBI
2	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
3	Wu Y and Wu PY: CD133 as a marker for cancer stem cells: Progresses and concerns. Stem Cells Dev. 18:1127–1134. 2009. View Article : Google Scholar : PubMed/NCBI
4	Irollo E and Pirozzi G: CD133: To be or not to be, is this the real question? Am J Transl Res. 5:563–581. 2013.PubMed/NCBI
5	Li Z: CD133: A stem cell biomarker and beyond. Exp Hematol Oncol. 2:172013. View Article : Google Scholar : PubMed/NCBI
6	Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R and Larocca LM: Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer. 117:162–174. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhao P, Lu Y, Jiang X and Li X: Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 102:1107–1111. 2011. View Article : Google Scholar : PubMed/NCBI
8	Wu S, Yu L, Wang D, Zhou L, Cheng Z, Chai D, Ma L and Tao Y: Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer. 12:5352012. View Article : Google Scholar : PubMed/NCBI
9	Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T and Takao S: CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 98:1389–1397. 2008. View Article : Google Scholar : PubMed/NCBI
10	Sasaki A, Kamiyama T, Yokoo H, Nakanishi K, Kubota K, Haga H, Matsushita M, Ozaki M, Matsuno Y and Todo S: Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep. 24:537–546. 2010. View Article : Google Scholar : PubMed/NCBI
11	Takahashi S, Kamiyama T, Tomaru U, Ishizu A, Shida T, Osaka M, Sato Y, Saji Y, Ozaki M and Todo S: Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep. 24:1201–1212. 2010. View Article : Google Scholar : PubMed/NCBI
12	Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S and Ikemoto T: CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol. 45:896–902. 2010. View Article : Google Scholar : PubMed/NCBI
13	Fan L, He F, Liu H, Zhu J, Liu Y, Yin Z, Wang L, Guo Y, Wang Z, Yan Q and Huang G: CD133: A potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer. 11:3202011. View Article : Google Scholar : PubMed/NCBI
14	Leelawat K, Thongtawee T, Narong S, Subwongcharoen S and Treepongkaruna SA: Strong expression of CD133 is associated with increased cholangiocarcinoma progression. World J Gastroenterol. 17:1192–1198. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hermansen SK, Christensen KG, Jensen SS and Kristensen BW: Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem. 59:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
16	Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 13:2236–2252. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hashimoto K, Aoyagi K, Isobe T, Kouhuji K and Shirouzu K: Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer. 17:97–106. 2014. View Article : Google Scholar : PubMed/NCBI
18	Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S and Scambia G: CD133 antigen expression in ovarian cancer. BMC Cancer. 9:2212009. View Article : Google Scholar : PubMed/NCBI
19	Fukamachi H, Shimada S, Ito K, Ito Y and Yuasa Y: CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation. Cancer Sci. 102:1313–1321. 2011. View Article : Google Scholar : PubMed/NCBI
20	Bauer N, Wilsch-Bräuninger M, Karbanová J, Fonseca AV, Strauss D, Freund D, Thiele C, Huttner WB, Bornhäuser M and Corbeil D: Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles-a role of the endocytic-exocytic pathway. EMBO Mol Med. 3:398–409. 2011. View Article : Google Scholar : PubMed/NCBI